ClinicalTrials.Veeva

Menu

Tumor Response in Hypofractionated Radiotherapy (TRHR)

P

Peking University

Status

Unknown

Conditions

Neoplasms

Study type

Observational

Funder types

Other

Identifiers

NCT02854449
20161022

Details and patient eligibility

About

This study will follow-up different immune cell populations in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of Local Hypofractionated Radiotherapy and a rationale for adjuvant immunotherapy.

Full description

  • Patient information and collection of a signed informed consent form

  • Clinical data collection

  • Blood samples of 5 mL:

    1. after registration, prior to the first fraction of radiotherapy
    2. during radiotherapy sessions
    3. one month, 3 months after the last radiotherapy session
  • Storage of the blood samples at ambient temperature

  • Transportation of the samples to the Institute of Biology of Lille (IBL) - CNRS UMR8161 for analysis

  • Destruction of the samples at the end of the analysis

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient requiring a hypofractionated irradiation;
  • pathologically confirmed Unspecified Adult Solid Tumor
  • Age ≥ 18 years old
  • KPS≥70
  • Signed written informed consent.

Exclusion criteria

  • Patient treated by chemotherapy, targeted or immunotherapy within 21 days before the first sampling,
  • Pregnant or breastfeeding woman,
  • Patient under guardianship or tutorship.

Trial contacts and locations

1

Loading...

Central trial contact

Bai Yun, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems